GLOBAL CARDIAC OUTPUT MONITORING SENSOR MARKET

 

INTRODUCTION

In order to assure tissue oxygenation in critically ill patients, normal practise calls for cardiac output monitoring, which has traditionally been carried out via a pulmonary artery catheter. The effectiveness of PAC, however, has been under scrutiny recently, with some arguing that its use may not only be unnecessary but also potentially detrimental.

 

This idea has significantly reduced the PAC’s widespread use, along with the availability of new, less intrusive cardiac output measuring devices. The ability to monitor or estimate cardiac output using a variety of technologies is now possible.

 

Some of these less intrusive tools give dynamic fluid responsiveness metrics and continually track stroke volume, While some offer continuous evaluation of central venous saturation using specialised catheters connected to the same monitor, others allow assessment of volumetric preload factors.

 

All of these factors, along with cardiac output, may lead to a more accurate assessment of the critically ill patient’s hemodynamics. Every device has inherent limits, though, and no cardiac output monitoring device can alter patient outcomes unless its use is combined with an intervention that has been shown to enhance patient outcomes on its own.

 

As a result, the idea of hemodynamic optimisation is becoming more widely accepted as a pillar in the care of critically sick patients and has been linked to better outcomes in both the perioperative and intensive care unit settings.

GLOBAL CARDIAC OUTPUT MONITORING SENSOR MARKET SIZE AND FORECAST

 

 

The Global Cardiac Output Monitoring Sensor market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

 

NEW PRODUCT LAUNCH

The new Reliant 2.0 system has been launched by Cheetah Medical, a supplier of noninvasive cardiac output and hemodynamic monitoring solutions. The Reliant 2.0 adds new parameters to provide a comprehensive suite of information for hemodynamic monitoring without the need for invasive modalities with the associated potential costs and risks, the company claimed.

 

These new parameters are in addition to core hemodynamic parameters such as cardiac output, cardiac index, and stroke volume. The updated parameters now include changes in thoracic fluid volume, noninvasive blood pressure, total peripheral resistance, stroke volume variation, and cardiac power.

 

The company claims that Cheetah’s patented Bioreactance Technology, which has been used successfully in over 2,000 patients in a variety of clinical settings including medical and surgical intensive care, perioperative care, emergency medicine, heart failure, hemodialysis, and exercise testing, powers the Reliant hemodynamic monitoring platform.

 

COMPANY PROFILE

• Cheetah Medical
• Healthcare
• Getinge AB
•  Edward Lifesciences Corporation
•  Philips, 
• BPL,
•  Contec;

 

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Cardiac Output Monitoring Sensor are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Cardiac Output Monitoring Sensor and key vendor selection criteria
3. Where is the Cardiac Output Monitoring Sensor manufactured? What is the average margin per unit?
4. Market share of Global Cardiac Output Monitoring Sensor market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Cardiac Output Monitoring Sensor in-house
6. key predictions for next 5 years in Global Cardiac Output Monitoring Sensor market
7. Average B-2-B Cardiac Output Monitoring Sensor market price in all segments
8. Latest trends in Cardiac Output Monitoring Sensor market, by every market segment
9. The market size (both volume and value) of the Cardiac Output Monitoring Sensor market in 2023-2030 and every year in between?
10. Production breakup of Cardiac Output Monitoring Sensor market, by suppliers and their OEM relationship